Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 6,200 Equity Shares on exercise of ESOP14-02-2024
14-02-2024
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation regarding Analyst/Investor Meet13-02-2024
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call Intimation18-01-2024
Gland Pharma Ltd - 543245 - Board Meeting Intimation for The Approval Of Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2023.
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 ,inter alia, to consider and approve Unaudited financial Results of the Company for the quarter and nine months ended December 31, 202311-01-2024
Gland Pharma Ltd - 543245 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) for the quarter ended December 31, 202311-01-2024
Gland Pharma Ltd - 543245 - Closure of Trading Window
Trading Window of the Company will be closed from January 01, 2024 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and nine months ending on December 31, 2023.29-12-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst / Investor Meet07-12-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of schedule of Analyst / Institutional Investor Meeting with Boyu Capital05-12-2023
Gland Pharma share price rise 6% after USFDA completes inspection of Hyderabad facility
Gland Pharma share price witnessed a 6.5% surge on Friday following the company's announcement that the United States Food and Drug Administration (USFDA) had successfully concluded its inspection of the Pashamylaram facility in Hyderabad.24-11-2023
Gland Pharma Ltd - 543245 - Receipt Of EIR From USFDA For Company''s Pashamylaram Facility
Receipt of EIR from US FDA for Company''s Pashamylaram Facility following the Pre-market Inspection covering US FDA''s Quality System/Current GMP regulations for Medical devices by US FDA between Aug 23, 2023 and Aug 26, 202324-11-2023